Kimberly N. Weaver

University of North Carolina at Chapel Hill — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index810citations52works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(25), SARS-CoV-2 and COVID-19 Research(19), Microscopic Colitis(14), Vaccine Coverage and Hesitancy(8), COVID-19 Clinical Research Studies(6)

Publications52 total

Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
UNC Libraries·2025Open Access
Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement
Tumori Journal·2025Open Access
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
UNC Libraries·2025Open Access
Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease
UNC Libraries·2025Open Access
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot
UNC Libraries·2025Open Access
Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys
JCI Insight·2024· 3 citedOpen Access
Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
Inflammatory Bowel Diseases·2024· 1 citedOpen Access
Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024Open Access
Tu1843 LONG-TERM EFFECTIVENESS AND DURABILITY OF SARS-COV-2 VACCINATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Gastroenterology·2024
Tu1844 MAGNITUDE OF SARS-COV-2 SPIKE ANTIBODY LEVEL FOLLOWING VACCINATION IS NOT ASSOCIATED WITH RISK OF DEVELOPING SYMPTOMATIC COVID-19 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Gastroenterology·2024
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology·2024· 4 cited
Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition·2024Open Access
Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry
The American Journal of Gastroenterology·2023· 54 citedOpen Access
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
UNC Libraries·2023Open Access
Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection
Journal of Crohn s and Colitis·2023· 6 cited
Very Early Pouchitis Is Associated with an Increased Likelihood of Chronic Inflammatory Conditions of the Pouch
Digestive Diseases and Sciences·2023· 11 cited
Engaging Multistakeholder Perspectives to Identify <scp>Patient‐Centered</scp> Research Priorities Regarding Vaccine Uptake Among Adults With Autoimmune Conditions
ACR Open Rheumatology·2023· 3 citedOpen Access
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot
Current Problems in Cancer·2023· 2 citedOpen Access
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
UNC Libraries·2022Open Access
COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety
PubMed·2022· 3 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Millie D. Long(34), Michael D. Kappelman(29), Francis A. Farraye(21), Jeremy Adler(18), Athos Bousvaros(18), Meenakshi Bewtra(18), Emanuelle Bellaguarda(18), Ann M. Firestine(18), Runa Watkins(17), Marla C. Dubinsky(17), Arthur Kastl(17), Ryan C. Ungaro(16), Kelly Chun(16), Xian Zhang(15), Xiangfeng Dai(15), Margie Boccieri(14), Michael Zikry(14), Hans Herfarth(14), Raymond K. Cross(12), Peter Higgins(10)